X0306 4 2022-08-24 0001706431 Vir Biotechnology, Inc. VIR 0001219042 NELSEN ROBERT 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 1 0 1 0 Common Stock 2022-08-24 4 J 0 217781 0 D 6714913 I See footnote Common Stock 2022-08-24 4 J 0 282219 0 D 8701750 I See footnote Common Stock 2022-08-24 4 J 0 27489 0 A 432679 D Common Stock 2022-08-24 4 J 0 1684 0 A 25483 I See footnote Common Stock 2022-08-25 4 J 0 217781 0 D 6497132 I See footnote Common Stock 2022-08-25 4 J 0 282219 0 D 8419531 I See footnote Common Stock 2022-08-25 4 J 0 27489 0 A 460168 D Common Stock 2022-08-25 4 J 0 1684 0 A 27167 I See footnote Distribution of Common Stock held by a limited partnership to its partners for no consideration. The shares are held by ARCH Venture Fund IX, L.P. ("ARCH IX"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX, L.P., which is the sole general partner of ARCH IX, and shares voting and investment control with respect to shares held by ARCH IX. The Reporting Person may be deemed to beneficially own the shares held by ARCH IX, and the Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein. The shares are directly held by ARCH Venture Fund IX Overage, L.P. ("ARCH Overage"). The Reporting Person is a managing director of ARCH Venture Partners IX, LLC, the sole general partner of ARCH Venture Partners IX Overage, L.P. ("Overage GPLP"), which is the sole general partner of ARCH Overage, and shares voting and investment control with respect to shares held by ARCH Overage. The Reporting Person disclaims ownership of such shares, except to the extent of his pecuniary interest therein. Change from indirect to direct ownership of shares previously reported as beneficially owned by the Reporting Person. Shares held by a trust for the benefit of family members of the Reporting Person. By: Robert Nelsen, Managing Director, By: /s/ Mark McDonnell, as Attorney-in-Fact 2022-08-26